A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC)
Status:
Active, not recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
A 2-part study, comprising of a 36-week placebo-controlled period and a 24-week open-label
extension period, to assess the efficacy and safety of 2 dose regimens of GB004 when added to
background UC therapy of 5-aminosalicylate (5-ASA) with or without systemic steroids.